Certain HPV16 antibodies may predict oropharyngeal cancer survival
the ONA take:
Certain human papillomavirus (HPV)-16 antibodies in the blood was associated with improved survival rates among patients with HPV-related oropharyngeal carcinoma, according to a new study.
For the study, researchers analyzed blood samples from 209 patients with previously untreated oropharyngeal carcinoma. Of those, 96 had confirmed HPV-positive disease. Samples were screened for HPV16 antibodies E1, E4-7, L1, L2, and the N-terminal and C-terminal fragments of E2.
Results showed that patients with any of the E antibodies had improved overall and progression-free survival versus those who tested negative for the antibodies. HPV-positive patients who tested positive for NE2, E1, or E6 antibodies also had a reduced mortality and disease progression risk.
Researchers found no survival advantage for people who tested positive for L antibodies.
Clinical trials are currently ongoing to evaluate whether vaccines can stimulate these antibodies to improve outcomes in patients with HPV-related cancers.
Certain HPV-16 antibodies in the blood associated with improved survival in HPV-related oropharyngeal carcinoma.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- Breast Conservation Improves Survival vs Mastectomy in Breast Cancer
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|